2021年华东医药股份有限公司三季报

Stock code: 000963 Stock abbreviation: Huadong Medicine Announcement No.: 2021-076 Huadong Medicine Co., Ltd. The Third Quarterly Report 2021 The Company and all members of the Board of Directors hereby guarantee that the information presented in this report is authentic, accurate and complete and free of any false records, misleading statements or material omissions. Important Declaration: 1.The Board of Directors, Board of Supervisors, directors, supervisors and senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the information presented in this report is authentic, accurate and complete and free of any false records, misleading statements or material omissions, and shall undertake indiv idual and joint legal liabilities. 2.The Company’s legal representative and the officer in charge of accounting, and head of accounting department (accounti ng supervisor) hereby declare and guarantee that the financial statements in this quarter report are authentic, accurate and complete. 3.Has the third quarterly report been audited? □Yes √ No This report is prepared both in Chi nese and English. Should there be any discrepancy between the Chinese and English versions, the Chinese versionshall prevail. I. Key financialdata (I) Key Accounting Data and Financial Indicators Whether the Company needs to perform retroactive adjustment or restatement of previous accounting data □Yes √ No Change from the The current reporting Change of the current From the beginning of the beginning of the year to period reporting period over the year to the end of the the end of the reporting same period last year reporting period period over the same period last year Operating revenue (yuan) 8,748,039,460.66 -1.04% 25,927,477,363.27 1.67% Net profit attributable to shareholders of listed 595,038,254.49 -9.88% 1,895,384,579.34 -20.74% companies (yuan) Net profit attributable to 568,039,187.19 -9.00% 1,762,020,074.37 -13.24% shareholders of listed companies after deducting non-recurring gains/losses (yuan) Net cash flow from operating activities —— —— 2,105,916,826.72 10.73% (yuan) Basic earnings per share 0.3401 -9.88% 1.0832 -20.74% (yuan/share) Diluted earnings per 0.3401 -9.88% 1.0832 -20.74% share (yuan/share) Weighted average return 3.75% -1.00% 12.28% -5.41% on equity (ROE) End of the current End of last year Change of the end of the current reporting period reporting period over the end of last year Totalassets (yuan) 27,687,711,922.81 24,201,348,154.75 14.41% Owners’ equity attributable to 16,250,585,502.88 14,619,821,308.60 11.15% shareholders of listed companies (yuan) Share capitalof the Company as of the trading day before disclosure : Share capitalof the Company as of the trading day before 1,749,809,548 disclosure (share) Fully diluted earnings per share calculated on the basis of the latest Share capita l Dividends pa id on preferred shares 0.00 Perpetualbond interest paid (yuan) 0.00 Fully diluted earnings per share calculated on the basis of the 1.0832 latest Share capital(yuan/s hare) (II)Items andamounts of non-recurring gains/losses √Applicable □ N/A Amount (from the Item Amount of the current beginning of the year to Note reporting period the end of the reporting period) Gains/losses on disposa lof non-current assets (including the written-off part of the accrued assets -356,832.47 -466,951.55 impairment reserve) Government grants included in current gains/losses(excluding those close ly re lated to nor ma l 19,665,596.43 157,973,691.62 operating activities, in line with national policies and measured according to unified nat iona lstandards) Receivables subject to separate impa irme nt test and 5,388,185.00 reversalof reserve for impairment Other non-operating income or expenditure 2,888,378.89 -2,028,188.08 Less:Amount affected by income tax -2,745,429.38 19,349,865. 15 Amount affected by minority interest (after tax) -2,056,495.07 8,152,366.87 Total 26,999,067.30 133,364,504.97 -- Details of other gains/losses items satisfying the definition of non-recurring gains/losses: □Applicable √ N/A No such case. If the Company recognizes a non-recurring ga in/ loss listed in the “Interpretative Announcement No. 1 on Information Disclosure Criteria for Public Companies – Non-Recurring Profit/Loss” as a recurring gain/loss, reasons should be specified. □Applicable √ N/A No such case. (III)Changes in key accounting data and financial indicators and their reasons √Applicable □ N/A Unit: RMB yuan Balance sheet item End of the period Beginning of the Change rate Notes on cause of changes period Accounts receivable 572,080,968.64 828,659,217.25 -30.96%Mainly due to ba nker’s acceptance discount in financing the current period Accounts receivable 8,147,812,875.63 6,137,675,568.82 32.75%Mainly due to income growth and capital return fluctuation Other receivables 299,688,469.54 87,269,489.82 243. 41% Mainly due to the increase of equity transfer accounts receivable and suspense accounts receivable Other current assets 38,039,156.52 85,654,691.58 -55.59%Mainly due to the decrease of input VAT to be deducted at the end of the period Other equity instruments 129,841,291.42 225,453,120.05 -42.41%Mainly due to the transfer of equity instrument investment investme nt of Ningbo DonghaiBank and the sale of some RAPT shares in the current period Goodwill 2,100,106,651.09 1,469,617,262.10 42.90%Mainly due to the acquisition of Doer Biologics and H igh Tech in the current period Notes payable 1,381,336,643.84 554,336,058.71 149. 19% Mainly due to the increase of billpayment in the current period Contract liabilities 186,487,690.02 94,384,629.77 97.58%Mainly due to the increase of advance drug payments in the current period Non-current liabilities due 23,288,386.11 67,813,886.68 -65.66%Mainly due to the decrease of long-term within one year payables and long-term borrow ing due within one year Long-term payables 164,454,591.48 26,812,354.90 513. 35% Mainly due to the increase in contingent and deferred consideration resulting from the acquisition of externalcompanies by the subs idiar ies Long term loan 287,439,900.00 151,611,367.86 89.59%Mainly due to the increase of subsidiaries’ long-term borrowing Other comprehensive 91,912,418.43 -2,191,069.45 4294.87%Mainly due to the increase in the exchange income differences from translation of fore ign currency statements Income s tate ment item Amount of the Amount of the Change rate Notes on cause of changes